<div class="headers"><div>Figure 1. RBS and SFS in patients with UC. Percentage change from baseline in RBS in the overall ITT (A), TNF antagonist–naive (B), and TNF antagonist–exposed (C) populations and in SFS in the overall ITT (D), TNF antagonist–naive (E), and TNF antagonist–exposed (F) populations after VDZ or PBO administration. aData points represent adjusted % change from BL mean, where adjustment is for subscore BL value and treatment. Error bars represent SE. bDifference adjusted o%f c9h5a%ngCeI[V<D0Z i-nPdiBcOat]e¼s asdtajutisstteicdalmseiagnni% change from BL for VDZ – adjusted mean % change from BL for PBO. Upper limit <U+FB01>cance at a nominal signi<U+FB01>cance level of 0.05. *Statistical signi<U+FB01>cance and non-signi<U+FB01>cance. Patients with baseline RBS ¼ 0 or SFS ¼ 0 were excluded from this analysis. Of note, the number of patients varies per study population at Weeks 2, 4, and 6 and is reported below the x-axis. BL, baseline; CI, con<U+FB01>dence interval; ITT, intent-to-treat; NS, nonsigni<U+FB01>cance; PBO, placebo; RBS, rectal bleeding subscore; SFS, stool frequency subscore; VDZ, vedolizumab.</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<thead>
<tr>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey;'> </th>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey; text-align: center;'>row/col</th>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey; text-align: center;'>19(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'>1</td>
<td style='border-bottom: 2px solid grey; text-align: left;'>1</td>
<td style='border-bottom: 2px solid grey; text-align: left;'><p class="">Figure 1. RBS and SFS in patients with UC. Percentage change from baseline in RBS in the overall ITT (A), TNF antagonist–naive (B), and TNF antagonist–exposed (C) populations and in SFS in the overall ITT (D), TNF antagonist–naive (E), and TNF antagonist–exposed (F) populations after VDZ or PBO administration. aData points represent adjusted % change from BL mean, where adjustment is for subscore BL value and treatment. Error bars represent SE. bDifference adjusted o%f c9h5a%ngCeI[V<D0Z i-nPdiBcOat]e¼s asdtajutisstteicdalmseiagnni% change from BL for VDZ – adjusted mean % change from BL for PBO. Upper limit <U+FB01>cance at a nominal signi<U+FB01>cance level of 0.05. *Statistical signi<U+FB01>cance and non-signi<U+FB01>cance. Patients with baseline RBS ¼ 0 or SFS ¼ 0 were excluded from this analysis. Of note, the number of patients varies per study population at Weeks 2, 4, and 6 and is reported below the x-axis. BL, baseline; CI, con<U+FB01>dence interval; ITT, intent-to-treat; NS, nonsigni<U+FB01>cance; PBO, placebo; RBS, rectal bleeding subscore; SFS, stool frequency subscore; VDZ, vedolizumab.</p></td>
</tr>
</tbody>
</table>
